|
|
|
|
As the field advances, adaptive methodologies and regulatory shifts redefine early-phase oncology trials, promoting efficiency, flexibility, and equitable access. The integration of these strategies not only accelerates development timelines but also ensures that novel treatments reach patients in a timely and effective manner.
|
|
|
|
|
Over the past 10 years, the introduction of immuno-oncology (IO) therapies has brought about a revolutionary change in the treatment of cancer patients worldwide. Learn how to plan for success and reduce risk when developing novel treatments for patients with cancer.
|
|
|
|
|
Through careful planning, aligned incentives, and an open, adaptive mindset, master protocols become powerful engines for accelerating therapies to market—particularly in high-need therapeutic areas. This paper provides a roadmap for navigating the operational and relational demands of master protocols.
|
|
|
|
|
Project FrontRunner represents a paradigm shift in oncology drug development, championing earlier-line studies to bring novel treatments to patients sooner. As case studies validate this approach, FrontRunner is poised to redefine the trajectory of cancer therapy approval.
|
|
|
|
|
|
|
|
2025 Global Oncology Trends Report
|
The IQVIA Institute for Human Data Science's 2025 report, Global Oncology Trends 2025, provides an in-depth analysis of the evolving global cancer landscape, highlighting significant trends in incidence, treatment innovation, and spending. Download now.
|
|
|
|
|
|
|
|
|
|
|
|
|
